INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administrationEnriched IP...
TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023...
NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q2 and Half Year...
Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a...
World-first take-home approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE /...
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated...
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified...
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified...
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end...
ATLANTA, GA / ACCESSWIRE / August 22, 2023 / The story of Lainie Jones, a cancer survivor from Fort Lauderdale,...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Banner Health and nference, a science-first software company transforming healthcare by making biomedical data computable, today announced a...
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancerSALT LAKE CITY,...
REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22,...
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and...
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate...
Julia Macharey Photograph of Julia Macharey standing up and looking into the camera.ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS22...
Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,...
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’...
London, UK – 22 August 2023 Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on...
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across PolandBERKELEY,...